Eloxx Pharmaceuticals vs Evaxion A/S
ELOX and EVAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELOX and EVAX compare
Evaxion A/S grew revenue faster over the last twelve months (125% versus −100% for Eloxx Pharmaceuticals).
Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 2 for Evaxion A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELOX | EVAX |
|---|---|---|
| Size and price | ||
| Market cap | $51.5M | – |
| Share price | $12.75 | $2.77 |
| Change, 1 year | 1158990% | −51.5% |
| Change, 5 years | −97.9% | −98.9% |
| Beta (5Y) | – | 1.29 |
| Employees | 7 | 45 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.1× | – |
| Growth | ||
| Revenue growth (TTM) | −100% | 125% (better) |
| Profitability | ||
| Operating margin | – | −123% |
| Net margin | – | −102% |
| FCF margin | – | −88.2% |
| Return on equity | −54.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −2.3× |
| Current ratio | 3.74 | 5.06 (better) |
| Altman Z-score | −4.46 | – |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 71.8% | 0.38% |
| Held by insiders | 42.6% | 3.5% |
| Short interest, % of float | 2.3% | – |
Go deeper
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
- EVAX stock overview
- EVAX income statement
- EVAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.